311 related articles for article (PubMed ID: 19584228)
1. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α.
Ji X; Wang H; Zhu J; Zhu L; Pan H; Li W; Zhou Y; Cong Z; Yan F; Chen S
Int J Cancer; 2014 Aug; 135(3):574-84. PubMed ID: 24374745
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Rapisarda A; Zalek J; Hollingshead M; Braunschweig T; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Hewitt SM; Shoemaker RH; Melillo G
Cancer Res; 2004 Oct; 64(19):6845-8. PubMed ID: 15466170
[TBL] [Abstract][Full Text] [Related]
5. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis.
Nam SY; Ko YS; Jung J; Yoon J; Kim YH; Choi YJ; Park JW; Chang MS; Kim WH; Lee BL
Br J Cancer; 2011 Jan; 104(1):166-74. PubMed ID: 21119667
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
7. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
9. Leukemia regression by vascular disruption and antiangiogenic therapy.
Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
[TBL] [Abstract][Full Text] [Related]
10. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
[TBL] [Abstract][Full Text] [Related]
11. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
12. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
13. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Rapisarda A; Uranchimeg B; Scudiero DA; Selby M; Sausville EA; Shoemaker RH; Melillo G
Cancer Res; 2002 Aug; 62(15):4316-24. PubMed ID: 12154035
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
Terzuoli E; Donnini S; Giachetti A; Iñiguez MA; Fresno M; Melillo G; Ziche M
Clin Cancer Res; 2010 Aug; 16(16):4207-16. PubMed ID: 20682710
[TBL] [Abstract][Full Text] [Related]
16. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
[TBL] [Abstract][Full Text] [Related]
17. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.
Kim YJ; Lee HJ; Kim TM; Eisinger-Mathason TS; Zhang AY; Schmidt B; Karl DL; Nakazawa MS; Park PJ; Simon MC; Yoon SS
Int J Cancer; 2013 Jan; 132(1):29-41. PubMed ID: 22684860
[TBL] [Abstract][Full Text] [Related]
18. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
[TBL] [Abstract][Full Text] [Related]
20. Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis.
Yang T; Yao Q; Cao F; Liu Q; Liu B; Wang XH
Int J Nanomedicine; 2016; 11():6679-6692. PubMed ID: 27994464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
